Myeloproliferative neoplasms: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 0
• JAK 25
• TP53 1
• PDGFR 0
• STAT3 0
• PI3K 0
• ERK 1
• FGFR 1
• FLT3 3
• mTOR 0
• AKT 0
• BCL-2 2
• IDH 3
• JNK 0
• HIF-1 0
• CSF1R 3
• HSP90 0
• MAPK 0
• MEK 2
• AMPK 0
• CD123 0
• CD19 0
• CD38 0
• IL-6 0
• KMT2A 0
• MDM2 0
• MYC 0
• NRF2 0
• PPAR 0
• RAS 0
• RUNX1 0
• ATM 0
• CD33 1
• CD40 0
• CDK4/6 1
• CXCR4 0
• EZH2 0
• G6PD 0
• HDAC 0
• KRAS 0
• NF1 0
• NLRP3 0
• NOTCH1 0
• NPM1 0
• NTRK 0
• PD-1 0
• PD-L1 0
• SGLT2 0
• SIRT1 0
• YAP 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, United States· US$407,543 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Developing a rapid sterility solution to deliver Time to Detection for autologous CAR-T Cell Therapies

  Mango, Inc.· Los Angeles, United States· US$306,817 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · K99

  The role of TET2 clonal hematopoiesis on solid tumor immunology

  University of Tx Md Anderson Can Ctr· Houston, United States· US$134,974 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  The Role of Cell Competition in Shaping the Clonal Structure of Hematopoiesis

  Washington University· Saint Louis, United States· US$465,749 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Identification of novel genetic regulators governing leukaemic transformation from myeloid proliferative neoplasms (MPN2AML)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €313,395· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of CD24 and CD24hi Neutrophils in key co-morbidities associated with the MyeloProliferative Neoplasms (NeutroMPN)

  Universidad de Sevilla· Sevilla, Spain· EU contribution €209,915· until May 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies (Rewind-MF)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €1,999,313· until Mar 2029

8 of 223 running projects, newest first. Listed amounts together: US$118.0m + €2.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 4
• Proteomics 7
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 19
• Immunohistochemistry 2
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 22
• Magnetic Resonance Imaging 14
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 1

• CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

  Sci Transl Med, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.